{"title":"ASH亮点与评论：多发性骨髓瘤","authors":"B. Faiman, Aprn-Bc, Aocn, Faan","doi":"10.6004/jadpro.2021.12.3.28","DOIUrl":null,"url":null,"abstract":"Dr. Faiman considers the use of qualitative interviews to understand the patient perspective on the clinical benefits and tolerability of belamaf. She also highlights the safety profile and noninferiority of subcutaneous daratumumab compared with IV daratumumab, as described in the APOLLO trial. Finally, Dr. Faiman emphasizes the importance of achieving MRD negativity measured by multiparameter flow cytometry and next-generation sequencing.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"12 1","pages":"4 - 10"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ASH Highlights and Commentary: Multiple Myeloma\",\"authors\":\"B. Faiman, Aprn-Bc, Aocn, Faan\",\"doi\":\"10.6004/jadpro.2021.12.3.28\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dr. Faiman considers the use of qualitative interviews to understand the patient perspective on the clinical benefits and tolerability of belamaf. She also highlights the safety profile and noninferiority of subcutaneous daratumumab compared with IV daratumumab, as described in the APOLLO trial. Finally, Dr. Faiman emphasizes the importance of achieving MRD negativity measured by multiparameter flow cytometry and next-generation sequencing.\",\"PeriodicalId\":94110,\"journal\":{\"name\":\"Journal of the advanced practitioner in oncology\",\"volume\":\"12 1\",\"pages\":\"4 - 10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the advanced practitioner in oncology\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2021.12.3.28\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the advanced practitioner in oncology","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.6004/jadpro.2021.12.3.28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Dr. Faiman considers the use of qualitative interviews to understand the patient perspective on the clinical benefits and tolerability of belamaf. She also highlights the safety profile and noninferiority of subcutaneous daratumumab compared with IV daratumumab, as described in the APOLLO trial. Finally, Dr. Faiman emphasizes the importance of achieving MRD negativity measured by multiparameter flow cytometry and next-generation sequencing.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
